Skip to main content

Advertisement

SpringerLink
Log in

Influence of age on false positive rates of urine-based tumor markers

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Introduction

Several influencing factors on false positive rates (FPRs) of urine-based tumor markers in the detection of urothelial cancer (UC) have been identified. We evaluated age as a possible influencing factor.

Methods

Urinary cytology (Cyt), UroVysion (FISH), ImmunoCyt (uCyt+) and NMP22 were determined in 1,554 patients suspicious for UC of the bladder before cystoscopy and in case of cancer detection before TURB. Additionally, upper urinary tract imaging was performed. Maker sensitivity, specificity and FPRs were evaluated in the entire cohort and in subgroups divided by age into <50, ≥50–70 and ≥70 years. Contingency tables and the Cochrane Armitage tests were used for statistical comparisons.

Results

UC was found in 377 and no UC in 1,177 (75 %) patients. A total of 336 patients were diagnosed with UC of the bladder and 41 with UC of the upper urinary tract. Overall sensitivity and specificity for Cyt were 82 and 82 %: for FISH, 73 and 79 % and for uCyt+, 79 and 75 %, respectively. For NMP22, regardless of the exclusion criteria they were 72 and 34 % and after exclusion of urinary tract infection (UTI) or prior to manipulation 46 and 86 %, respectively. Significantly higher FPRs were found with increasing age for Cyt (p = 0.001), a trend to higher FPRs for uCyt+ (p = 0.11) and almost no difference for FISH (p = 0.63). For NMP22, differences became significant after exclusion of patients with UTI or prior manipulation (p = 0.02).

Conclusions

The results of the present study give evidence that false positive rates of Cyt and NMP22 increase with age indicating that age should be respected for their correct interpretation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Tilki D, Burger M, Dalbagni G et al (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60:484–492

    Article  PubMed  Google Scholar 

  2. Babjuk M, Oosterlinck W, Sylvester R et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008

    Article  PubMed  Google Scholar 

  3. Lotan Y, Svatek RS, Sagalowsky AI (2006) Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer 1(107):982–990

    Article  Google Scholar 

  4. Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF (2008) Screening for bladder cancer using urine-based tumor markers. Minerva Urol Nefrol 60:247–253

    PubMed  CAS  Google Scholar 

  5. Hennenlotter J, Huber S, Todenhofer T et al (2011) Point-of-care tests for bladder cancer: the influencing role of hematuria. Adv Urol 2011:937561

    Article  PubMed  Google Scholar 

  6. Pesch B, Nasterlack M, Eberle F et al (2011) The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int 108:546–552

    Article  PubMed  Google Scholar 

  7. Todenhofer T, Hennenlotter J, Witstruk M et al (2012) Influence of renal excretory function on the performance of urine based markers to detect bladder cancer. J Urol 187:68–73

    Article  PubMed  Google Scholar 

  8. Todenhofer T, Hennenlotter J, Tews V et al (2011) Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. Urol Oncol

  9. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH (2010) The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 105:300–308

    Article  PubMed  Google Scholar 

  10. Madeb R, Messing EM (2004) Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 22:86–92

    Article  PubMed  Google Scholar 

  11. Papanicolaou GN, Marshall VF (1945) Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 18(101):519–520

    Article  Google Scholar 

  12. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Pathol 29:1228–1242

    Article  Google Scholar 

  13. Riesz P, Lotz G, Paska C et al (2007) Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res 13:187–194

    Article  PubMed  Google Scholar 

  14. Kipp BR, Tyner HL, Campion MB et al (2008) Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer. Am J Clin Pathol 130:552–559

    Article  PubMed  CAS  Google Scholar 

  15. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M (1999) Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 161:1486–1489

    Article  PubMed  CAS  Google Scholar 

  16. Greene KL, Berry A, Konety BR (2006) Diagnostic utility of the immunoCyt/uCyt+ test in bladder cancer. Rev Urol 8:190–197

    PubMed  Google Scholar 

  17. Karakiewicz PI, Benayoun S, Zippe C et al (2006) Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 97:997–1001

    Article  PubMed  Google Scholar 

  18. Bubendorf L (2011) Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma—FISHing for the right catch. Acta Cytol 55:113–119

    Article  PubMed  CAS  Google Scholar 

  19. Hajdinjak T (2008) UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 26:646–651

    Article  PubMed  CAS  Google Scholar 

  20. Mian C, Maier K, Comploj E et al (2006) uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 25(108):60–65

    Article  Google Scholar 

  21. Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A (2009) Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol 43:461–466

    Article  PubMed  Google Scholar 

  22. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI (2008) Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 10:120–135

    PubMed  Google Scholar 

  23. Atsu N, Ekici S, Oge OO, Ergen A, Hascelik G, Ozen H (2002) False-positive results of the NMP22 test due to hematuria. J Urol 167:555–558

    Article  PubMed  Google Scholar 

  24. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A (1999) Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 162:53–57

    Article  PubMed  CAS  Google Scholar 

  25. Huber S, Schwentner C, Taeger D et al (2012) Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int

  26. Taylor JA 3rd, Kuchel GA (2009) Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol 6:135–144

    Article  PubMed  Google Scholar 

  27. Raitanen MP, Aine R, Rintala E et al (2002) Differences between local and review urinary cytology in diagnosis of bladder cancer an interobserver multicenter analysis. Eur Urol 41:284–289

    Article  PubMed  Google Scholar 

  28. Savic S, Zlobec I, Thalmann GN et al (2009) The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer 15(124):2899–2904

    Article  Google Scholar 

  29. Gofrit ON, Zorn KC, Silvestre J et al (2008) The predictive value of multi-targeted fluorescent in situ hybridization in patients with history of bladder cancer. Urol Oncol 26:246–249

    Article  PubMed  CAS  Google Scholar 

  30. Ponsky LE, Sharma S, Pandrangi L et al (2001) Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol 166:75–78

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Eberhard Karls University Tuebingen, Hoppe–Seyler, Str. 3, 72076, Tuebingen, Germany

    M. Horstmann, T. Todenhöfer, J. Hennenlotter, S. Aufderklamm, J. Mischinger, U. Kuehs, G. Gakis, A. Stenzl & C. Schwentner

  2. Department of Urology, Kantonsspital Winterthur, Brauerstr. 15, 8401, Winterthur, Switzerland

    M. Horstmann

Authors
  1. M. Horstmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Todenhöfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Hennenlotter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Aufderklamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Mischinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. U. Kuehs
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Gakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Stenzl
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Schwentner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Horstmann.

Additional information

M. Horstmann and T. Todenhöfer contributed equally to this publication.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horstmann, M., Todenhöfer, T., Hennenlotter, J. et al. Influence of age on false positive rates of urine-based tumor markers. World J Urol 31, 935–940 (2013). https://doi.org/10.1007/s00345-012-0906-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-012-0906-1

Keywords

Search

Navigation